BioDuro Appoints Scientific Advisors

BioDuro, a global contract research, development, and manufacturing organization (CRDMO), has appointed Andrew Thomas, Ph.D., and Stevan Djuric, Ph.D., as scientific advisors.

In these new roles, they will provide strategic guidance to clients and BioDuro’s scientific and operational teams, helping strengthen the company’s capabilities in innovative drug discovery and development.

Both advisors bring decades of global pharmaceutical R&D leadership experience and are already actively engaged in supporting BioDuro’s customers’ programs.

“We greatly value the insight and expertise provided by our scientific advisors,” said Armin Spura, Ph.D., CEO of BioDuro. “The appointment of Drs. Thomas and Djuric deepens our commitment to scientific excellence and innovation as we continue to expand our capabilities and support our partners in advancing complex drug discovery programs.”

About Andrew Thomas, Ph.D.

Thomas is an experienced pharmaceutical executive and entrepreneur with extensive leadership experience in medicinal chemistry. He previously served as Global Head of Medicinal Chemistry, Small Molecule Research at Roche, where he was a member of the company’s Therapeutics Modalities Leadership Team, and led global teams responsible for advancing innovative drug discovery programs across multiple therapeutic areas.

About Stevan Djuric, Ph.D.

Djuric is the former Vice President of Discovery Chemistry and Technology at AbbVie, where he led both the company’s medicinal and discovery chemistry teams. With more than three decades of experience in pharmaceutical research, he has played a role in advancing numerous drug discovery programs and has been recognized for his contributions to medicinal chemistry and innovation in drug discovery.